Banham AH - Search Results

1

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S. Nyman H, et al. Among authors: banham ah. Eur J Haematol. 2009 May;82(5):364-72. doi: 10.1111/j.1600-0609.2009.01222.x. Epub 2009 Jan 9. Eur J Haematol. 2009. PMID: 19141121

2

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppä S. Nyman H, et al. Among authors: banham ah. Mod Pathol. 2009 Aug;22(8):1094-101. doi: 10.1038/modpathol.2009.73. Epub 2009 May 15. Mod Pathol. 2009. PMID: 19448593 Free article.

3

t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.

Fenton JA, Schuuring E, Barrans SL, Banham AH, Rollinson SJ, Morgan GJ, Jack AS, van Krieken JH, Kluin PM. Fenton JA, et al. Among authors: banham ah. Genes Chromosomes Cancer. 2006 Feb;45(2):164-8. doi: 10.1002/gcc.20278. Genes Chromosomes Cancer. 2006. PMID: 16252263

4

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.

Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Barrans SL, et al. Blood. 2004 Nov 1;104(9):2933-5. doi: 10.1182/blood-2004-03-1209. Epub 2004 Jul 6. Blood. 2004. PMID: 15238418 Free article.

5

FOXP1: a potential therapeutic target in cancer.

Koon HB, Ippolito GC, Banham AH, Tucker PW. Koon HB, et al. Among authors: banham ah. Expert Opin Ther Targets. 2007 Jul;11(7):955-65. doi: 10.1517/14728222.11.7.955. Expert Opin Ther Targets. 2007. PMID: 17614763 Free PMC article. Review.

6

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.

Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Lawrie CH, et al. Among authors: banham ah. Br J Haematol. 2008 May;141(5):672-5. doi: 10.1111/j.1365-2141.2008.07077.x. Epub 2008 Mar 3. Br J Haematol. 2008. PMID: 18318758 Free article.

7

DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas.

Loo SK, Ch'ng ES, Lawrie CH, Muruzabal MA, Gaafar A, Pomposo MP, Husin A, Md Salleh MS, Banham AH, Pedersen LM, Møller MB, Green TM, Wong KK. Loo SK, et al. Among authors: banham ah. Pathology. 2017 Dec;49(7):731-739. doi: 10.1016/j.pathol.2017.08.009. Epub 2017 Oct 23. Pathology. 2017. PMID: 29074044

8

Is FOXP3 expressed in cutaneous T-cell lymphomas?

Banham AH, Brown PJ, Lyne L, Schulze HJ, Hallermann C. Banham AH, et al. Eur J Haematol. 2008 Jan;80(1):90-1. doi: 10.1111/j.1600-0609.2007.00990.x. Epub 2007 Nov 23. Eur J Haematol. 2008. PMID: 18036183 No abstract available.

9

Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.

Wong KK, Ch'ng ES, Loo SK, Husin A, Muruzabal MA, Møller MB, Pedersen LM, Pomposo MP, Gaafar A, Banham AH, Green TM, Lawrie CH. Wong KK, et al. Among authors: banham ah. Exp Mol Pathol. 2015 Dec;99(3):537-45. doi: 10.1016/j.yexmp.2015.08.019. Epub 2015 Sep 2. Exp Mol Pathol. 2015. PMID: 26341140

10

The significance of FOXP1 in diffuse large B-cell lymphoma.

Gascoyne DM, Banham AH. Gascoyne DM, et al. Among authors: banham ah. Leuk Lymphoma. 2017 May;58(5):1037-1051. doi: 10.1080/10428194.2016.1228932. Epub 2016 Sep 27. Leuk Lymphoma. 2017. PMID: 27678023 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page